loading page

A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: opportunities for precision medicine
  • +4
  • John Prensner,
  • Juan Putra,
  • Sara Vargas,
  • Alanna Church,
  • Katherine Janeway,
  • Nadine McCleary,
  • Steven DuBois
John Prensner
Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Corresponding Author:john_prensner@dfci.harvard.edu

Author Profile
Juan Putra
Boston Children's Hospital
Author Profile
Sara Vargas
Boston Children's Hospital
Author Profile
Alanna Church
Boston Children's Hospital
Author Profile
Katherine Janeway
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Author Profile
Nadine McCleary
Dana-Farber Cancer Institute
Author Profile
Steven DuBois
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Author Profile

Abstract

Cancer of unknown primary (CUP) is a common diagnosis in adult oncology, but is extremely rare in pediatrics, with few published reports and none in the era of molecular profiling. Here, we describe a 13-year old boy with metastatic adenocarcinoma of unknown primary that was refractory to conventional chemotherapy. Molecular profiling revealed an activating ERBB2 D769Y variant. He subsequently achieved disease control on a lapatinib-containing regimen, and upon progression, he transiently responded to neratinib prior to dying from disease. Our case reports a rare example of pediatric CUP and highlights the utility of molecular profiling in these cases.
12 Dec 2020Published in Pediatric Blood & Cancer. 10.1002/pbc.28780